BCL-2 (B-cell Lymphoma 2) Inhibitors Market to grow at a CAGR of 12.60% by 2026|Driven by the Rise in the Geriatric Population|17000+ Technavio Reports

To understand more about Market Dynamics. Download our FREE sample report

The BCL-2(B- cell lymphoma 2) inhibitors Market is expected to increase by USD 1.43 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.60% as per the latest market report by Technavio. 55% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for the BCL-2 (b-cell lymphoma 2) inhibitors market in North America. Market growth in this region will be slower than the growth of the market in Asia. The recent approvals of Venetoclax combinations in the US will facilitate the BCL-2 (b-cell lymphoma 2) inhibitors market growth in North America over the forecast period.

Download a FREE Sample: for more additional information about the key countries in North America

BCL-2 (B-cell lymphoma 2) Inhibitors Market 2022-2026: Scope

 The BCL-2 (b-cell lymphoma 2) inhibitors market report covers the following areas:

• BCL-2 (B-cell lymphoma 2) Inhibitors Market Size
• BCL-2 (B-cell lymphoma 2) Inhibitors Market Trends
• BCL-2 (B-cell lymphoma 2) Inhibitors Market Industry Analysis

Vendor Insights-

The BCL-2(B- cell lymphoma 2) inhibitors Market is concentrated, and the vendors are deploying growth strategies such as focusing on product delivery through multiple distribution channels to compete in the market.

• AbbVie Inc- The company offers BCL lymphoma Inhibitors under the brand name Venclyxto.

Find additional highlights on the vendors and their product offerings. Download a Free Sample Report

Latest Drivers & Trends Driving the Market-

• BCL-2(B- cell lymphoma 2) inhibitors Market Driver:
• The rise in the geriatric population:

The rise in the geriatric population is one of the key drivers supporting the BCL-2 (b-cell lymphoma 2) inhibitors market growth. According to the Centers for Disease Control and Prevention (CDC), the US geriatric population is expected to increase to 19.6% in 2030, while it was approximately 2.4% in 2000. The population of adults aged 80 years and above in the US was approximately 9.3 million in 2000, and it is expected to reach 19.5 million by 2030. As the geriatric population is an important sub-group that is more likely to be affected by indications such as CLL/SLL and AML in comparison to the young adult population, the market is expected to witness an increase in the patient population. Thus, as the geriatric population has been increasing globally, the patient pool for indications such as CLL/SLL and AML is expected to grow

• BCL-2(B- cell lymphoma 2) inhibitors Market Trend:
• Increase of patient assistance programs:

The increase of patient assistance programs is a major trend supporting the BCL-2 (b-cell lymphoma 2) inhibitors market growth. For instance, Genentech introduced a co-pay assistance program, BioOncology Co-pay. The program provides financial support to patients with specific disease states. Under this program, the company provides a range of offerings to eligible patients with financial support, including those who are commercially insured, government-insured, and uninsured and those covered by Medicare and Medicaid. This helps patients to access treatment using VENCLEXTA at an affordable price. Such effective patient assistance programs and reimbursement programs are expected to support the adoption of the high-cost regimen of BCL-2 inhibitors to a large extent, which would promote market growth during the forecast period. 

Find additional information about various other market Drivers & Trends mentioned in our FREE sample report.

Didn't Find What You Were Looking For? Customize Report-

Don't miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer USD 1,000 worth of FREE customization at the time of purchase. Speak to our Analyst now!

BCL-2 (B-cell lymphoma 2) Inhibitors Market 2022-2026: Key Highlights

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will assist BCL-2 (b-cell lymphoma 2) inhibitors market growth during the next five years
• Estimation of the BCL-2 (b-cell lymphoma 2) inhibitors market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the BCL-2 (b-cell lymphoma 2) inhibitors market
• Analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of BCL-2 (b-cell lymphoma 2) inhibitors market vendors

Related Reports 

• The ear infection treatment market share is expected to increase by USD 3.67 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. Download a free sample now!
• The central nervous system (CNS) stimulant drugs market share is expected to increase by USD 5.95 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.74%. Download a free sample now!

Table of Contents:

***1. Executive Summary                           

                **1.1     Market Overview            

                                *Exhibit 01:  Key Finding 1

                                *Exhibit 02:  Key Finding 2

                                *Exhibit 03:  Key Finding 3

                                *Exhibit 04:  Key Finding 5

                                *Exhibit 05:  Key Finding 6

                                *Exhibit 06:  Key Finding 7

                                *Exhibit 07:  Key Finding 8

***2. Market Landscape

                **2.1 Market ecosystem             

                                *2.1.1 Parent Market

                                *Exhibit 08  Parent market

                                *Exhibit 09:  Market characteristics

                **2.2 Value Chain Analysis          

                                *Exhibit 10:  Value Chain Analysis: Pharmaceuticals

                                *2.2.1    Research and development (R&D) and drug discovery:

                                *2.2.2    Integration and product development:

                                *2.2.3    Manufacturing:

                                *2.2.4    Outbound logistics:

                                *2.2.5    Marketing and sales:

                                *2.2.6    Support services:

                                *2.2.7    Innovation

***3. Market Sizing                       

                **3.1 Market definition

                                *Exhibit 11:  Offerings of vendors included in the market definition

                **3.2 Market segment analysis 

                                *Exhibit 12:  Market segments

                **3.3 Market size 2021 

                **3.4 Market outlook: Forecast for 2021 - 2026 

                                *Exhibit 13:  Global - Market size and forecast 2021 - 2026 ($ million)

                                *Exhibit 14:  Global market: Year-over-year growth 2021 - 2026 (%)

***4. Five Forces Analysis                          

                **4.1 Five Forces Summary        

                                *Exhibit 15:  Five forces analysis 2021 - 2026

                **4.2 Bargaining power of buyers           

                                *Exhibit 16: Bargaining power of the buyer

                **4.3 Bargaining power of suppliers       

                                *Exhibit 17: Bargaining power of the supplier

                **4.4 Threat of new entrants    

                                *Exhibit 18: Threat of new entrants

                **4.5 Threat of substitutes         

                                *Exhibit 19: Threat of substitutes

                **4.6 Threat of rivalry   

                                *Exhibit 20: Threat of rivalry

                **4.7 Market condition

                                *Exhibit 21: Market condition - Five forces 2021

***5. Market Segmentation by Product

                **5.1 Market segments

                                *Exhibit 22:  Product Market share 2021 - 2026 (%)

                **5.2 Comparison by  Product   

                                *Exhibit 23:  Comparison by  Product

                **5.3 Combination therapy - Market size and forecast 2021-2026              

                                *Exhibit 24:   Combination therapy -  Market size and forecast 2021-2026 ($ million)

                                *Exhibit 25:   Combination therapy - Year-over-year growth 2021-2026 (%)

                **5.4 Monotherapy - Market size and forecast 2021-2026             

                                *Exhibit 26: Monotherapy - Market size and forecast 2021-2026 ($ million)

                                *Exhibit 27: Monotherapy - Year-over-year growth 2021-2026 (%)

                **5.5 Market opportunity by Product    

                                *Exhibit 28:  Market opportunity by Product

***6. Customer landscape                         

                                *Technavio's customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                **6.1 Overview

                                *Exhibit 29:  Customer landscape

***7. Geographic Landscape                     

                **7.1 Geographic segmentation

                                *Exhibit 30:  Market share by geography 2021-2026 (%)

                **7.2 Geographic comparison   

                                *Exhibit 31:  Geographic comparison

                **7.3 North America - Market size and forecast 2021-2026           

                                *Exhibit 32:   North America - Market size and forecast 2021-2026($ million)

                                *Exhibit 33:  North America - Year-over-year growth 2021-2026 (%)

                **7.4 Europe- Market size and forecast 2021-2026           

                                *Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)

                                *Exhibit 35:  Europe- Year-over-year growth 2021-2026 (%)

                **7.5 Asia- Market size and forecast 2021-2026  

                                *Exhibit 36:  Asia - Market size and forecast 2021-2026 ($ million)

                                *Exhibit 37: Asia - Year-over-year growth 2021-2026(%)

                **7.6 ROW - Market size and forecast 2021-2026              

                                *Exhibit 38:  ROW - Market size and forecast 2021-2026 ($ million)

                                *Exhibit 39:  ROW - Year-over-year growth 2021-2026 (%)

                **7.7 Key leading countries        

                                *Exhibit 40:  Key leading countries

                **7.8 Market opportunity by geography

                                *Exhibit 41:  Market opportunity by geography ($ million)

***8. Drivers, Challenges, and Trends                   

                **8.1 Market drivers     

                                *8.1.1    Rise in geriatric population

                                *8.1.2    Growing awareness about hematological malignancies

                                *8.1.3    High target affinity and specificity of BCL-2 inhibitors

                **8.2 Market challenges              

                                *8.2.1    Availability of substitutes

                                *Exhibit 42:  Some of the substitute drugs for BCL-2 inhibitor lead molecule:

                                *8.2.2    Adverse effects of BCL-2 inhibitors

                                *8.2.3    Drug resistance

                                *Exhibit 43:  Impact of drivers and challenges

                **8.3 Market trends      

                                *8.3.1    Increase of patient assistance programs

                                *8.3.2    Growing approval of combination therapy

                 *8.3.3    Development of novel formulations

***9. Vendor Landscape                             

                **9.1 Overview

                                *Exhibit 44:  Vendor landscape

                **9.2 Landscape disruption        

                                *Exhibit 45:  Landscape disruption

                                *Exhibit 46: Industry Risk

                **9.3 Competitive Scenario        

***10. Vendor Analysis               

                **10.1 Vendors covered              

                                *Exhibit 47: Vendors covered

                **10.2 Market positioning of vendors    

                                *Exhibit 48: Market positioning of vendors?

                **10.3  AbbVie Inc.        

                                *Exhibit 49:  AbbVie Inc. - Overview

                                *Exhibit 50:  AbbVie Inc. - Product and service

                                *Exhibit 51:  AbbVie Inc. - Key offerings

                **10.4  Ascentage Pharma Group International

                                *Exhibit 52:  Ascentage Pharma Group International  - Overview

                                *Exhibit 53:  Ascentage Pharma Group International  - Business segments

                                *Exhibit 54:  Ascentage Pharma Group International  - Key offerings

                                *Exhibit 55:  Ascentage Pharma Group International  - Segment focus

                **10.5  AstraZeneca Plc

                                *Exhibit 56:  AstraZeneca Plc - Overview

                                *Exhibit 57:  AstraZeneca Plc - Product and service

                                *Exhibit 58:  AstraZeneca Plc - Key offerings

                **10.6  BioGene Ltd.     

                                *Exhibit 59:  BioGene Ltd. - Overview

                                *Exhibit 60:  BioGene Ltd. - Product and service

                                *Exhibit 61:  BioGene Ltd. - Key offerings

                *10.7     F. Hoffmann La Roche Ltd

                               *Exhibit 62:  F. Hoffmann La Roche Ltd. - Overview         

                             *Exhibit 63:  F. Hoffmann La Roche Ltd. - Business segments       

                              *Exhibit 64:  F. Hoffmann La Roche Ltd. - Key offerings   

                              *Exhibit 65:  F. Hoffmann La Roche Ltd. - Segment focus

                **10.8  Servier

                                *Exhibit 66:  Servier  - Overview

                                *Exhibit 67:  Servier  - Business segments

                                *Exhibit 68:  Servier  - Key offerings

                                *Exhibit 69:  Servier  - Segment focus

***11. Appendix                            

                **11.1 Scope of the report         

                                *11.1.1 Market definition

                                *11.1.2 Objectives

                                *11.1.3 Notes and caveats

                **11.2 Currency conversion rates for US$            

                                *Exhibit 70: Currency conversion rates for US$?

                **11.3 Research Methodology 

                                *Exhibit 71:Research Methodology

                                *Exhibit 72:Validation techniques employed for market sizing?

                                *Exhibit 73: Information sources

                **11.4 List of abbreviations        

                                *Exhibit 74: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio